TICKERNERD
Menu
BBNXBBNXHealthcare · Medical Devices

BBNX Stock Forecast: Beta Bionics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$17
−4.84% on the day

The 15 Wall Street analysts covering Beta Bionics, Inc. hold a median 12-month price target of $25 — +49.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$948.4M
Ticker Nerd rank
31/ 100
Median analyst target
$25
Analysts covering
15
Revenue$32.0M+37.8% y/y
Operating income−$25.6M
Net income−$23.4M
Free cash flow−$15.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.7%
1M
−11.9%
YTD
−45.1%
1Y
−37.5%
From 52W high
−47.7%
From 52W low
+88.8%
$9
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BBNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Beta Bionics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
31/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
58
Revisions
57
Size
45
Issuance
45
Momentum
44
Accruals
36
Volatility
34
Value
33
Quality
28

Growth (58): Sales and profits are climbing, and climbing faster than before.

Quality (28): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BBNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BBNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26BBNXHigh $30Median $25Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
11 Buy4 Hold0 Sell
Low $16Median $25High $30

The green dot is the last close — the median target sits +49.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
28 Oct 2026Piper SandlerReiteratesOverweight$20 → $24
28 Oct 2026TD CowenMaintainsHold$18 → $21
12 Oct 2026JefferiesInitiatesBuy$30
24 Sept 2026Truist SecuritiesMaintainsBuy—
24 Sept 2026Truist SecuritiesMaintainsBuy$23 → $28
23 Sept 2026Wells FargoInitiatesOverweight—
23 Sept 2026Wells FargoInitiatesOverweight$28
15 Sept 2026B of A SecuritiesMaintainsNeutral$18 → $20
15 Sept 2026B of A SecuritiesMaintainsNeutral—
15 Sept 2026BairdMaintainsNeutral—
15 Sept 2026BairdMaintainsNeutral$14 → $16
15 Sept 2026Truist SecuritiesReiteratesBuy—
15 Sept 2026Truist SecuritiesReiteratesBuy$22 → $23
14 Sept 2026Leerink PartnersMaintainsOutperform—
14 Sept 2026Leerink PartnersMaintainsOutperform$24 → $27
21 Aug 2026William BlairInitiatesMarket Perform—
21 Aug 2026William BlairInitiatesMarket Perform—
28 July 2026UBSAssumesBuy$22
15 July 2026Goldman SachsMaintainsBuy—
15 July 2026Goldman SachsMaintainsBuy$17 → $19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BBNX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BBNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Beta Bionics, Inc. returned −37.5% against +12.4% for the S&P 500, dividends included.

BBNX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26BBNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BBNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Beta Bionics, Inc. (BBNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.4×

Cheaper than 93% of US stocks

Price / sales
7.3×

Cheaper than 17% of US stocks

Price / book
2.3×

Cheaper than 38% of US stocks

EV / EBITDA
−8.0×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
30.3%

Higher than 78% of US stocks

Earnings growth (YoY)
37.8%

Higher than 70% of US stocks

Gross margin
59.0%

Higher than 72% of US stocks

Operating margin
−74.9%

Higher than 15% of US stocks

Net margin
−65.3%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−23.9%

Higher than 30% of US stocks

Return on assets
−15.0%

Higher than 23% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Beta Bionics, Inc. (BBNX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Beta Bionics, Inc. has a market value of $948.4M and an enterprise value of $721.7M.

  • Revenue in the twelve months to 30 June 2026: $119.0M. The latest quarter grew 30.3% year on year.

  • Net income over the same four quarters: −$73.0M, a −61.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.65.

  • Free cash flow in the twelve months to 30 June 2026: −$61.4M.

  • Shares outstanding: 45.0M.

  • Trailing P/E: −9.4×; forward P/E: −8.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Beta Bionics, Inc. employs 420 people — $283K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

BBNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BBNXBeta Bionics, Inc.$948.4M31
QDELQuidelOrtho Corp.$903.5M36
SIBNSI-BONE, Inc.$937.6M72
KIDSOrthoPediatrics Corp.$806.0M79
IRMDIRadimed Corp.$980.5M81
CTKBCytek Biosciences, Inc.$791.6M80
AHCOAdaptHealth Corp.$789.7M48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Beta Bionics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BBNX news & analysis

BBNX DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc. Investors They Have Until November 3rd to Seek Lead Plaintiff Role with the Firm

GlobeNewsWire · 31 Oct 2026negative

Bragar Eagel & Squire reminded Beta Bionics investors that November 3 is the deadline to seek a lead plaintiff role. Litigation Partner Brandon Walker invited investors who suffered losses to contact him to discuss their options.

Why it matters — BBNX investors may wish to note the stated deadline and the opportunity to discuss participation in the litigation.

Kaplan Fox Encourages Beta Bionics, Inc. (BBNX) Investors With Significant Losses to Take Action Before the November 3, 2026 Lead Plaintiff Deadline

Newsfile Corp · 30 Oct 2026negative

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Beta Bionics on behalf of investors who acquired its common stock from July 30, 2025, through February 24, 2026. The firm noted a November 3, 2026, lead plaintiff deadline.

Why it matters — The lawsuit and lead plaintiff deadline are developments for BBNX investors to monitor.

BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

PRNewsWire · 29 Oct 2026negative

Rosen Law Firm reminded Beta Bionics common-stock purchasers from July 30, 2025 through February 24, 2026 of a November 3, 2026 deadline to seek lead plaintiff status in a securities fraud lawsuit. The firm said eligible purchasers may be entitled to compensation through a contingency-fee arrangement.

Why it matters — The notice concerns a securities lawsuit involving BBNX and sets a deadline for investors from the stated class period.

FAQ

Frequently asked questions about BBNX stock

What is the BBNX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Beta Bionics, Inc. have a median 12-month price target of $25, with estimates ranging from $16 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BBNX stock a buy right now?

Of the 15 analysts covering Beta Bionics, Inc., 11 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beta Bionics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BBNX?

As at 31 Oct 2026, Beta Bionics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (58 of 100).

Will BBNX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +49.4% from the last close, and Ticker Nerd's factor model ranks Beta Bionics, Inc. 31 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BBNX stock forecast for 2030?

No analyst covering Beta Bionics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $30 over the next 12 months.

How has BBNX stock performed over the past year?

Beta Bionics, Inc. returned -37.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Beta Bionics, Inc. do?

Beta Bionics Inc. is a commercial-stage medical device company focused on automated insulin delivery for people with insulin-requiring diabetes.

What is the latest news on BBNX?

The most recent item we track (GlobeNewsWire, 31 Oct 2026): "BBNX DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc. Investors They Have Until November 3rd to Seek Lead Plaintiff Role with the Firm". Bragar Eagel & Squire reminded Beta Bionics investors that November 3 is the deadline to seek a lead plaintiff role. Litigation Partner Brandon Walker invited investors who suffered losses to contact him to discuss their options.

Company

About Beta Bionics, Inc.

Beta Bionics Inc. is a commercial-stage medical device company focused on automated insulin delivery for people with insulin-requiring diabetes. Its core product, the iLet Bionic Pancreas, is designed to simplify day-to-day diabetes management by using adaptive closed-loop algorithms to determine insulin dosing. Beta Bionics offers systems and related solutions for adults and children with type 1 diabetes, alongside supporting software and connected tools that help streamline treatment workflows. The company operates in the diabetes technology and medical devices markets, where it addresses the needs of patients, caregivers, and healthcare providers seeking more integrated insulin management solutions. Headquartered in Irvine, California, Beta Bionics plays a role in advancing device-based diabetes care through commercially available products centered on automated insulin delivery.

CEO Mr. Sean T. Saint PE · 420 employees · United States · https://www.betabionics.com